Jennifer A. Pietenpol

Affiliations: 
Vanderbilt University, Nashville, TN 
Area:
Cell Biology, Molecular Biology, Microbiology Biology
Google:
"Jennifer Pietenpol"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, et al. (2020) Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science Translational Medicine. 12
Lehmann BD, Abramson VG, Sanders M, et al. (2019) TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Beeler JS, Marshall CB, Gonzalez-Ericsson PI, et al. (2019) p73 regulates epidermal wound healing and induced keratinocyte programming. Plos One. 14: e0218458
Santos Guasch GL, Beeler JS, Marshall CB, et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. Iscience. 8: 236-249
Jovanovic B, Mayer IA, Mayer EL, et al. (2017) A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Lehmann BD, Jovanović B, Chen X, et al. (2016) Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. Plos One. 11: e0157368
Marshall CB, Mays DJ, Beeler JS, et al. (2016) p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Cell Reports
Ring BZ, Hout DR, Morris SW, et al. (2016) Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. Bmc Cancer. 16: 143
Lehmann BD, Pietenpol JA. (2015) Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast (Edinburgh, Scotland). 24: S36-40
Mohni KN, Thompson PS, Luzwick JW, et al. (2015) A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Plos One. 10: e0125482
See more...